Investigational Drug Information for MLN0128
✉ Email this page to a colleague
What is the drug development status for MLN0128?
MLN0128 is an investigational drug.
There have been 39 clinical trials for MLN0128.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2015.
The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are one hundred and nine US patents protecting this investigational drug and one international patent.
Summary for MLN0128
| US Patents | 109 |
| International Patents | 1,206 |
| US Patent Applications | 551 |
| WIPO Patent Applications | 326 |
| Japanese Patent Applications | 102 |
| Clinical Trial Progress | Phase 2 (2015-07-01) |
| Vendors | 74 |
Recent Clinical Trials for MLN0128
| Title | Sponsor | Phase |
|---|---|---|
| Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study | M.D. Anderson Cancer Center | Phase 1/Phase 2 |
| Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for MLN0128
Top disease conditions for MLN0128
Top clinical trial sponsors for MLN0128
US Patents for MLN0128
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| MLN0128 | ⤷ Try a Trial | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | ⤷ Try a Trial |
| MLN0128 | ⤷ Try a Trial | Treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) | ⤷ Try a Trial |
| MLN0128 | ⤷ Try a Trial | Method of targeting glycoproteins to treat cancer | Board of Regents of the University of Nebraska (Lincoln, NE) | ⤷ Try a Trial |
| MLN0128 | ⤷ Try a Trial | Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-- trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use | Signal Pharmaceuticals, LLC (San Diego, CA) | ⤷ Try a Trial |
| MLN0128 | ⤷ Try a Trial | Heterocyclic estrogen receptor modulators and uses thereof | Genentech, Inc. (South San Francisco, CA) | ⤷ Try a Trial |
| MLN0128 | ⤷ Try a Trial | Estrogen receptor mutations and uses thereof | FOUNDATION MEDICINE, INC. (Cambridge, MA) | ⤷ Try a Trial |
| MLN0128 | ⤷ Try a Trial | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MLN0128
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| MLN0128 | Australia | AU2014348657 | 2033-11-13 | ⤷ Try a Trial |
| MLN0128 | Australia | AU2017245411 | 2033-11-13 | ⤷ Try a Trial |
| MLN0128 | Australia | AU2019246853 | 2033-11-13 | ⤷ Try a Trial |
| MLN0128 | Brazil | BR112016010716 | 2033-11-13 | ⤷ Try a Trial |
| MLN0128 | Canada | CA2929181 | 2033-11-13 | ⤷ Try a Trial |
| MLN0128 | China | CN105899232 | 2033-11-13 | ⤷ Try a Trial |
| MLN0128 | Eurasian Patent Organization | EA201690987 | 2033-11-13 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
